Difference between revisions of "Malignant solid neoplasm, EGFR-mutated"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "http://ascopubs.org" to "https://ascopubs.org") |
|||
(22 intermediate revisions by 3 users not shown) | |||
Line 1: | Line 1: | ||
− | < | + | <span id="BackToTop"></span> |
− | + | <div class="noprint" style="background-color:LightGray; position:fixed; bottom:2%; right:0.25%; padding-left:5px; padding-right:5px; margin: 15px; opacity:0.8; border-style: solid; border-color:DarkGray; border-width: 1px"> | |
− | + | [[#top|Back to Top]] | |
− | + | </div> | |
{| class="wikitable" style="float:right; margin-right: 5px;" | {| class="wikitable" style="float:right; margin-right: 5px;" | ||
|- | |- | ||
Line 9: | Line 9: | ||
|} | |} | ||
{{TOC limit|limit=3}} | {{TOC limit|limit=3}} | ||
− | |||
− | |||
=All lines of therapy= | =All lines of therapy= | ||
==Erlotinib monotherapy {{#subobject:e0d17a|Regimen=1}}== | ==Erlotinib monotherapy {{#subobject:e0d17a|Regimen=1}}== | ||
+ | <div class="toccolours" style="background-color:#eeeeee"> | ||
===Regimen {{#subobject:392a4b|Variant=1}}=== | ===Regimen {{#subobject:392a4b|Variant=1}}=== | ||
− | {| class="wikitable" style="width: | + | {| class="wikitable sortable" style="width: 60%; text-align:center;" |
− | !style="width: | + | !style="width: 33%"|Study |
− | !style="width: | + | !style="width: 33%"|Dates of enrollment |
+ | !style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
|- | |- | ||
− | |[https:// | + | |[https://doi.org/10.1200/JCO.2017.75.3780 Hainsworth et al. 2018 (MyPathway)] |
− | |style="background-color:#ffffbe"|Phase | + | |2014-2016 |
+ | |style="background-color:#ffffbe"|Phase 2a, fewer than 20 pts in this arm | ||
|- | |- | ||
|} | |} | ||
− | ==== | + | <div class="toccolours" style="background-color:#fdcdac"> |
− | *EGFR nonsynonymous exon 18 or exon 21 mutations, or exon 19 deletions | + | ====Biomarker eligibility criteria==== |
− | ==== | + | *Gene: EGFR |
− | *[[Erlotinib (Tarceva)]] 150 mg PO once per day | + | *Alteration: nonsynonymous exon 18 or exon 21 [[Biomarkers#SNV|mutations]], or exon 19 [[Biomarkers#Deletion|deletions]] |
− | + | *Acceptable methods of measurement: molecular profiling performed on tissue obtained at the most recent tumor biopsy | |
− | ''' | + | *Biomarker exclusions: EGFR exon 20 [[Biomarkers#SNV|mutations]] |
− | + | </div> | |
+ | <div class="toccolours" style="background-color:#b3e2cd"> | ||
+ | ====Targeted therapy==== | ||
+ | *[[Erlotinib (Tarceva)]] 150 mg PO once per day on days 1 to 28 | ||
+ | '''28-day cycles''' | ||
+ | </div></div> | ||
===References=== | ===References=== | ||
− | # '''MyPathway:''' Hainsworth JD, Meric-Bernstam F, Swanton C, Hurwitz H, Spigel DR, Sweeney C, Burris H, Bose R, Yoo B, Stein A, Beattie M, Kurzrock R. Targeted therapy for advanced solid tumors on the basis of molecular profiles: results from MyPathway, an open-label, phase IIa multiple basket study. J Clin Oncol. 2018 Feb 20;36(6):536-542. Epub 2018 Jan 10. [https:// | + | # '''MyPathway:''' Hainsworth JD, Meric-Bernstam F, Swanton C, Hurwitz H, Spigel DR, Sweeney C, Burris H, Bose R, Yoo B, Stein A, Beattie M, Kurzrock R. Targeted therapy for advanced solid tumors on the basis of molecular profiles: results from MyPathway, an open-label, phase IIa multiple basket study. J Clin Oncol. 2018 Feb 20;36(6):536-542. Epub 2018 Jan 10. [https://doi.org/10.1200/JCO.2017.75.3780 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/29320312/ PubMed] [https://clinicaltrials.gov/study/NCT02091141 NCT02091141] |
− | + | [[Category:Malignant solid neoplasm, EGFR-mutated regimens]] | |
− | [[Category:EGFR regimens]] | ||
[[Category:Biomarker-specific pages]] | [[Category:Biomarker-specific pages]] | ||
− | [[Category: | + | [[Category:Malignant solid neoplasm]] |
Latest revision as of 00:59, 3 December 2023
1 regimens on this page
1 variants on this page
|
All lines of therapy
Erlotinib monotherapy
Regimen
Study | Dates of enrollment | Evidence |
---|---|---|
Hainsworth et al. 2018 (MyPathway) | 2014-2016 | Phase 2a, fewer than 20 pts in this arm |
Biomarker eligibility criteria
References
- MyPathway: Hainsworth JD, Meric-Bernstam F, Swanton C, Hurwitz H, Spigel DR, Sweeney C, Burris H, Bose R, Yoo B, Stein A, Beattie M, Kurzrock R. Targeted therapy for advanced solid tumors on the basis of molecular profiles: results from MyPathway, an open-label, phase IIa multiple basket study. J Clin Oncol. 2018 Feb 20;36(6):536-542. Epub 2018 Jan 10. link to original article contains dosing details in manuscript PubMed NCT02091141